STOCK TITAN

Beyond Air™ Scheduled to Announce Fiscal Year 2020 Financial Results on Monday, June 22nd

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Beyond Air, Inc. (NASDAQ: XAIR) announced financial results for the fiscal fourth quarter and year ended March 31, 2020, to be reported after market close on June 22, 2020. The management team will host a conference call and webcast at 4:30 p.m. ET on the same day. Beyond Air is developing the LungFit™ system to deliver inhaled nitric oxide for treating pulmonary diseases, including severe lung infections and pulmonary hypertension. The device has the potential to generate up to 400 ppm of nitric oxide, which may address conditions inadequately treated by existing methods.

Positive
  • None.
Negative
  • None.

GARDEN CITY, N.Y., June 08, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced it will report financial results for its fiscal fourth quarter and year ended March 31, 2020 after the market closes on Monday, June 22, 2020. The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. Eastern Time the same day. 

100%; border-collapse:collapse !important;">
Conference Call & Webcast Details: 
12%; width:12%; min-width:12%;">Date and Time: 88%; width:88%; min-width:88%;">Monday, June 22nd @ 4:30 p.m. ET
Domestic:877-407-0784
International: 201-689-8560
Passcode: 13704923
Webcast: http://public.viavid.com/index.php?id=140183

About Beyond Air, Inc.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit™ can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit™ for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

CONTACT
Steven Lisi, Chief Executive Officer
Beyond Air, Inc. 
Slisi@beyondair.net

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com  
(212) 915-2577


FAQ

When will Beyond Air report its financial results for the fourth quarter of 2020?

Beyond Air will report its financial results for the fiscal fourth quarter on June 22, 2020, after market close.

What time is Beyond Air's conference call scheduled for June 22, 2020?

The conference call is scheduled for 4:30 p.m. Eastern Time on June 22, 2020.

What is the ticker symbol for Beyond Air?

The ticker symbol for Beyond Air is XAIR.

What is the LungFit™ system developed by Beyond Air?

The LungFit™ system is a device designed to deliver inhaled nitric oxide for the treatment of various pulmonary diseases.

What conditions is Beyond Air targeting with its LungFit™ system?

Beyond Air is targeting serious lung infections and pulmonary hypertension with its LungFit™ system.

Beyond Air, Inc.

NASDAQ:XAIR

XAIR Rankings

XAIR Latest News

XAIR Stock Data

30.54M
58.22M
16.36%
36.4%
2.01%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
GARDEN CITY